ONCY - Oncolytics Biotech - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

50.41M

Cash

29.6M

Avg Qtr Burn

-7.022M

Short % of Float

0.89%

Insider Ownership

3.85%

Institutional Own.

1.91%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Pelareorep + gemcitabine, nab-paclitaxel, atezolizumab Details Cancer, Pancreatic cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + paclitaxel + avelumab (Bavencio®) Details Breast cancer, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + Retifanlimab Details Breast cancer, Triple-negative breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + modified FOLFIRINOX Details Pancreatic cancer, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep +/- Atezolizumab Details Cancer, Breast cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + Atezolizumab (Tecentriq) Details Gastric cancer, Colorectal cancer , Cancer, Pancreatic cancer, Squamous cell carcinoma of the anal canal	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pelareorep + Keytruda® Details Pancreatic cancer, Sarcoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.